{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:35:40Z","timestamp":1789767340111,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12664-021-01220-5","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:02:22Z","timestamp":1647118942000},"page":"169-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3158-5318","authenticated-orcid":false,"given":"Tadashi","family":"Namisaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Shimozato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ozutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihisa","family":"Fujinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kawaratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Mitoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"1220_CR1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/hepr.13437","volume":"50","author":"Y Ogawa","year":"2020","unstructured":"Ogawa Y, Kobayashi T, Honda Y, et al. Metabolomic\/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: a multicenter study. Hepatol Res. 2020;50:955\u201365.","journal-title":"Hepatol Res"},{"key":"1220_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/hepr.13495","volume":"50","author":"C Inadomi","year":"2020","unstructured":"Inadomi C, Takahashi H, Ogawa Y, et al. Accuracy of the enhanced liver fibrosis test, and combination of the enhanced liver fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res. 2020;50:682\u201392.","journal-title":"Hepatol Res"},{"key":"1220_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/hepr.13508","volume":"50","author":"S Oeda","year":"2020","unstructured":"Oeda S, Takahashi H, Imajo K, et al. Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: comparison between M and XL probes. Hepatol Res. 2020;50:831\u20139.","journal-title":"Hepatol Res"},{"key":"1220_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/hepr.13502","volume":"50","author":"Y Eguchi","year":"2020","unstructured":"Eguchi Y, Wong G, Akhtar O, Sumida Y. Non-invasive diagnosis of non-alcoholic steatohepatitis and advanced fibrosis in Japan: a targeted literature review. Hepatol Res. 2020;50:645\u201355.","journal-title":"Hepatol Res"},{"key":"1220_CR5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365.","journal-title":"Hepatology"},{"key":"1220_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/hepr.13543","volume":"50","author":"T Shida","year":"2020","unstructured":"Shida T, Oshida N, Suzuki H, et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan. Hepatol Res. 2020;50:1032\u201346.","journal-title":"Hepatol Res"},{"key":"1220_CR7","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","volume":"62","author":"V Ratziu","year":"2015","unstructured":"Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65-75.","journal-title":"J Hepatol"},{"key":"1220_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13293-015-0033-y","volume":"6","author":"F Mauvais-Jarvis","year":"2015","unstructured":"Mauvais-Jarvis F. Sex differences in metabolic homeostasis, diabetes, and obesity. Biol Sex Differ. 2015;6:14.","journal-title":"Biol Sex Differ"},{"key":"1220_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/hep.31312","volume":"73","author":"J Vandel","year":"2021","unstructured":"Vandel J, Dubois-Chevalier J, Gheeraert C, et al. Hepatic molecular signatures highlight the sexual dimorphism of nonalcoholic steatohepatitis (NASH). Hepatology. 2021;73:920\u201336.","journal-title":"Hepatology"},{"key":"1220_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00535-010-0311-8","volume":"46 Suppl 1","author":"E Hashimoto","year":"2011","unstructured":"Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol. 2011;46 Suppl 1:63\u20139.","journal-title":"J Gastroenterol"},{"key":"1220_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u201365.","journal-title":"Lancet"},{"key":"1220_CR12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3892\/mmr.2014.2995","volume":"11","author":"A Douhara","year":"2015","unstructured":"Douhara A, Moriya K, Yoshiji H, et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep. 2015;11:1693\u2013700.","journal-title":"Mol Med Rep"},{"key":"1220_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1749-6632.1998.tb09016.x","volume":"851","author":"L Bertok","year":"1998","unstructured":"Bertok L. Effect of bile acids on endotoxin in vitro and in vivo (physico-chemical defense). Bile deficiency and endotoxin translocation. Ann N Y Acad Sci. 1998;851:408\u201310.","journal-title":"Ann N Y Acad Sci"},{"key":"1220_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/hepr.13385","volume":"49","author":"N Shimozato","year":"2019","unstructured":"Shimozato N, Namisaki T, Kaji K, et al. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. Hepatol Res. 2019;49:1147\u201361.","journal-title":"Hepatol Res"},{"key":"1220_CR15","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1101\/gad.12.20.3149","volume":"12","author":"B Blumberg","year":"1998","unstructured":"Blumberg B, Evans RM. Orphan nuclear receptors\u2013new ligands and new possibilities. Genes Dev. 1998;12:3149\u201355.","journal-title":"Genes Dev"},{"key":"1220_CR16","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","volume":"175","author":"P Fickert","year":"2009","unstructured":"Fickert P, Fuchsbichler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol. 2009;175:2392\u2013405.","journal-title":"Am J Pathol"},{"key":"1220_CR17","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184\u201396.","journal-title":"Lancet"},{"key":"1220_CR18","first-page":"88","volume":"74","author":"VU Buko","year":"2002","unstructured":"Buko VU, Lukivskaya OY, Zavodnik LV, Sadovnichy VV, Petushok NE, Tauschel ND. Antioxidative effect of ursodeoxycholic acid in the liver of rats with oxidative stress caused by gamma-irradiation. Ukr Biokhim Zh. 2002;74:88\u201392.","journal-title":"Ukr Biokhim Zh"},{"key":"1220_CR19","first-page":"7","volume":"54","author":"E Bjornsson","year":"2008","unstructured":"Bjornsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2008;54:7\u201318.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"1220_CR20","doi-asserted-by":"publisher","first-page":"287348","DOI":"10.1155\/2015\/287348","volume":"2015","author":"X Dai","year":"2015","unstructured":"Dai X, Wang B. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2015;2015:287348.","journal-title":"Gastroenterol Res Pract."},{"key":"1220_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0168-8278(02)00104-6","volume":"37","author":"H Yoshiji","year":"2002","unstructured":"Yoshiji H, Yoshii J, Ikenaka Y, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol. 2002;37:22\u201330.","journal-title":"J Hepatol"},{"key":"1220_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2174\/1568009043332790","volume":"4","author":"H Yoshiji","year":"2004","unstructured":"Yoshiji H, Kuriyama S, Noguchi R, Fukui H. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets. 2004;4:555\u201367.","journal-title":"Curr Cancer Drug Targets"},{"key":"1220_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000069792","volume":"23","author":"H Yoshiji","year":"2002","unstructured":"Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002;23:348\u201356.","journal-title":"Tumour Biol"},{"key":"1220_CR24","first-page":"81","volume":"28","author":"H Yoshiji","year":"2011","unstructured":"Yoshiji H, Noguchi R, Ikenaka Y, et al. Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development. Int J Mol Med. 2011;28:81\u20138.","journal-title":"Int J Mol Med"},{"key":"1220_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/jhep.2001.28231","volume":"34","author":"H Yoshiji","year":"2001","unstructured":"Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745\u201350.","journal-title":"Hepatology"},{"key":"1220_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/hepr.13281","volume":"49","author":"Y Sawada","year":"2019","unstructured":"Sawada Y, Kawaratani H, Kubo T, et al. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. Hepatol Res. 2019;49:284\u201395.","journal-title":"Hepatol Res"},{"key":"1220_CR27","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/hep4.1104","volume":"1","author":"T Namisaki","year":"2017","unstructured":"Namisaki T, Moriya K, Kitade M, et al. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. Hepatol Commun. 2017;1:928\u201345.","journal-title":"Hepatol Commun"},{"key":"1220_CR28","doi-asserted-by":"publisher","first-page":"e0163069","DOI":"10.1371\/journal.pone.0163069","volume":"11","author":"S Pelusi","year":"2016","unstructured":"Pelusi S, Petta S, Rosso C, et al. Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease. PLoS One. 2016;11:e0163069.","journal-title":"PLoS One"},{"key":"1220_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","volume":"65","author":"MC Michel","year":"2013","unstructured":"Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65:809\u201348.","journal-title":"Pharmacol Rev"},{"key":"1220_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1681\/ASN.V4140","volume":"4","author":"A Remuzzi","year":"1993","unstructured":"Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 1993;4:40\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1220_CR31","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.4254\/wjh.v8.i28.1194","volume":"8","author":"K Asada","year":"2016","unstructured":"Asada K, Aihara Y, Takaya H, et al. DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis. World J Hepatol. 2016;8:1194\u20139.","journal-title":"World J Hepatol"},{"key":"1220_CR32","unstructured":"Nakae D, Yoshiji H, Mizumoto Y et\u2009al. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 1992; 52: 5042\u2013 5045"},{"key":"1220_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/hepr.12008","volume":"43","author":"R Noguchi","year":"2013","unstructured":"Noguchi R, Yoshiji H, Ikenaka Y, et al. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. Hepatol Res. 2013;43:765\u201374.","journal-title":"Hepatol Res"},{"key":"1220_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1220_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00535-015-1104-x","volume":"51","author":"T Namisaki","year":"2016","unstructured":"Namisaki T, Noguchi R, Moriya K, et al. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. J Gastroenterol. 2016;51:162\u201372.","journal-title":"J Gastroenterol"},{"key":"1220_CR36","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fphar.2017.00350","volume":"8","author":"V Caputi","year":"2017","unstructured":"Caputi V, Marsilio I, Cerantola S, et al. Toll-like receptor 4 modulates small intestine neuromuscular function through nitrergic and purinergic pathways. Front Pharmacol. 2017;8:350.","journal-title":"Front Pharmacol"},{"key":"1220_CR37","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.4049\/jimmunol.1402598","volume":"195","author":"S Guo","year":"2015","unstructured":"Guo S, Nighot M, Al-Sadi R, Alhmoud T, Nighot P, Ma TY. Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88. J Immunol. 2015;195:4999\u20135010.","journal-title":"J Immunol"},{"key":"1220_CR38","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","volume":"64","author":"M Ubeda","year":"2016","unstructured":"Ubeda M, Lario M, Munoz L, et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol. 2016;64:1049\u201357.","journal-title":"J Hepatol"},{"key":"1220_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/jgh.12112","volume":"28","author":"Y Shirai","year":"2013","unstructured":"Shirai Y, Yoshiji H, Noguchi R, et al. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2013;28:723\u201330.","journal-title":"J Gastroenterol Hepatol"},{"key":"1220_CR40","doi-asserted-by":"publisher","first-page":"6164","DOI":"10.4049\/jimmunol.171.11.6164","volume":"171","author":"M Bruewer","year":"2003","unstructured":"Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171:6164\u201372.","journal-title":"J Immunol"},{"key":"1220_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","volume":"185","author":"L Verbeke","year":"2015","unstructured":"Verbeke L, Farre R, Verbinnen B, et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015;185:409\u201319.","journal-title":"Am J Pathol"},{"key":"1220_CR42","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1124\/jpet.105.084905","volume":"314","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther. 2005;314:584\u201395.","journal-title":"J Pharmacol Exp Ther"},{"key":"1220_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1124\/jpet.105.085597","volume":"315","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther. 2005;315:58\u201368.","journal-title":"J Pharmacol Exp Ther"},{"key":"1220_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1386-6346(03)00160-8","volume":"27","author":"H Yoshiji","year":"2003","unstructured":"Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. Hepatol Res. 2003;27:51\u20136.","journal-title":"Hepatol Res"},{"key":"1220_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1756-3305-6-199","volume":"6","author":"YM Attia","year":"2013","unstructured":"Attia YM, Elalkamy EF, Hammam OA, Mahmoud SS, El-Khatib AS. Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection. Parasit Vectors. 2013;6:199.","journal-title":"Parasit Vectors"},{"key":"1220_CR46","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10620-006-9133-1","volume":"52","author":"U Tox","year":"2007","unstructured":"Tox U, Scheller I, Kociok N, et al. Expression of angiotensin II receptor type 1 is reduced in advanced rat liver fibrosis. Dig Dis Sci. 2007;52:1995\u20132005.","journal-title":"Dig Dis Sci"},{"key":"1220_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1349-7006.1994.tb02386.x","volume":"85","author":"D Nakae","year":"1994","unstructured":"Nakae D, Mizumoto Y, Yoshiji H, et al. Different roles of 8-hydroxyguanine formation and 2-thiobarbituric acid-reacting substance generation in the early phase of liver carcinogenesis induced by a choline-deficient, L-amino acid-defined diet in rats. Jpn J Cancer Res. 1994;85:499\u2013505.","journal-title":"Jpn J Cancer Res"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-021-01220-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T02:09:43Z","timestamp":1652666983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-021-01220-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s12664-021-01220-5","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]},"assertion":[{"value":"8 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TN, KK, NS, DK, TO, YT, YF, KK, MF, SS, YS,\u00a0 NN, HT, YO, KS, HK, KM, RN, KA, TA, AM, and HY declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer\/publishers are responsible for the results\/findings and content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}